SRF acquires Kanpur Plastipack's CPP business to bolster offerings
The deal, which is expected to be in the range of ₹100 crore, will enable SRF to expand and complement its existing offerings ...
Yahoo Finance19d
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α ...
Nasdaq18d
Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development
KPL-387 is an independently developed monoclonal ... potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the ...